A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Cardiovascular Disease
Phase of Trial: Phase III
Latest Information Update: 03 Dec 2014
At a glance
- Drugs Fenofibrate/simvastatin (Primary) ; Fenofibrate; Simvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.